NCT02362997 2026-02-12Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHLDana-Farber Cancer InstitutePhase 2 Completed82 enrolled 20 charts
NCT03331341 2025-08-05Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin LymphomaUniversity of WashingtonPhase 1/2 Completed50 enrolled 10 charts
NCT02453594 2024-10-29Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)Merck Sharp & Dohme LLCPhase 2 Completed211 enrolled 22 charts
NCT02665650 2019-05-16Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaAffimed GmbHPhase 1 Completed30 enrolled